Optimizing_VBG antibiotics_NNS in_IN residents_NNS of_IN nursing_NN homes_NNS :_: protocol_NN of_IN a_DT randomized_VBN trial_NN Abstract_NP |_SYM Background_NN |_SYM Antibiotics_NNS are_VBP frequently_RB prescribed_VBN for_IN older_JJR adults_NNS who_WP reside_VBP in_IN long-term_JJ care_NN facilities_NNS ._SENT A_DT substantial_JJ proportion_NN of_IN antibiotic_JJ use_NN in_IN this_DT setting_NN is_VBZ inappropriate_JJ ._SENT Antibiotics_NNS are_VBP often_RB prescribed_VBN for_IN asymptomatic_JJ bacteriuria_NNS ,_, a_DT condition_NN for_IN which_WDT randomized_VBD trials_NNS of_IN antibiotic_JJ therapy_NN indicate_VBP no_DT benefit_NN and_CC in_IN fact_NN harm_NN ._SENT This_DT proposal_NN describes_VBZ a_DT randomized_VBN trial_NN of_IN diagnostic_JJ and_CC therapeutic_JJ algorithms_NNS to_TO reduce_VB the_DT use_NN of_IN antibiotics_NNS in_IN residents_NNS of_IN long-term_JJ care_NN facilities_NNS ._SENT Methods_NNS |_SYM In_IN this_DT on-going_JJ study_NN ,_, 22_CD nursing_NN homes_NNS have_VBP been_VBN randomized_VBN to_TO either_DT use_NN of_IN algorithms_NNS (_( 11_CD nursing_NN homes_NNS )_) or_CC to_TO usual_RB practise_VB (_( 11_CD nursing_NN homes_NNS )_) ._SENT The_DT algorithms_NNS describe_VBP signs_NNS and_CC symptoms_NNS for_IN which_WDT it_PP would_MD be_VB appropriate_JJ to_TO send_VB urine_NN cultures_NNS or_CC to_TO prescribe_VB antibiotics_NNS ._SENT The_DT algorithms_NNS are_VBP introduced_VBN by_IN inservicing_VBG nursing_NN staff_NN and_CC by_IN conducting_VBG one-on-one_JJ sessions_NNS for_IN physicians_NNS using_VBG case-scenarios_NNS ._SENT The_DT primary_JJ outcome_NN of_IN the_DT study_NN is_VBZ courses_NNS of_IN antibiotics_NNS per_IN 1000_CD resident_JJ days_NNS ._SENT Secondary_JJ outcomes_NNS include_VBP urine_NN cultures_NNS sent_VBN and_CC antibiotic_JJ courses_NNS for_IN urinary_JJ indications_NNS ._SENT Focus_NN groups_NNS and_CC semi-structured_JJ interviews_NNS with_IN key_JJ informants_NNS will_MD be_VB used_VBN to_TO assess_VB the_DT process_NN of_IN implementation_NN and_CC to_TO identify_VB key_JJ factors_NNS for_IN sustainability_NN ._SENT Antibiotic_JJ use_NN in_IN long-term_JJ care_NN facilities_NNS |_SYM Antibiotics_NNS are_VBP frequently_RB prescribed_VBN for_IN older_JJR adults_NNS who_WP reside_VBP in_IN long-term_JJ care_NN facilities_NNS (_( LTCFs_NP )_) ._SENT The_DT reported_VBN prevalence_NN of_IN antibiotic_JJ use_NN in_IN nursing_VBG home_NN residents_NNS ranges_NNS from_IN 8_CD %_NN to_TO 17_CD %_NN ._SENT Prospective_JJ studies_NNS of_IN antibiotic_JJ use_NN in_IN these_DT facilities_NNS demonstrate_VBP that_IN 50_CD %_NN to_TO 75_CD %_NN of_IN residents_NNS are_VBP exposed_VBN to_TO at_IN least_JJS one_CD course_NN of_IN antibiotics_NNS over_IN a_DT one_CD year_NN period_NN ._SENT There_EX are_VBP several_JJ important_JJ risks_NNS associated_VBN with_IN the_DT use_NN of_IN antibiotics_NNS in_IN residents_NNS of_IN LTCFs_NP ._SENT First_RB ,_, there_EX is_VBZ the_DT risk_NN of_IN developing_VBG multi-drug_NN antibiotic_JJ resistance_NN with_IN exposure_NN to_TO antibiotics_NNS ._SENT Second_RB ,_, there_EX is_VBZ the_DT risk_NN of_IN drug-related_JJ adverse_JJ effects_NNS ._SENT In_IN a_DT study_NN of_IN antibiotic_JJ use_NN in_IN Ontario_NP facilities_NNS which_WDT provide_VBP chronic_JJ care_NN ,_, 6_CD %_NN of_IN individuals_NNS developed_VBD an_DT adverse_JJ effect_NN ._SENT Because_IN polypharmacy_NN in_IN this_DT population_NN is_VBZ common_JJ ,_, the_DT risk_NN for_IN harmful_JJ drug_NN interactions_NNS in_IN addition_NN to_TO adverse_JJ reactions_NNS to_TO antibiotics_NNS is_VBZ high_JJ ._SENT Third_JJ ,_, the_DT increased_VBN use_NN of_IN antibiotics_NNS in_IN LTCFs_NP results_NNS in_IN significant_JJ costs_NNS ._SENT In_IN a_DT study_NN of_IN antibiotic_JJ use_NN in_IN Manitoba_NP nursing_NN homes_NNS for_IN example_NN ,_, over_IN $257,000_NN was_VBD spent_VBN on_IN antibiotics_NNS in_IN the_DT 1988_CD --_: 89_CD fiscal_JJ year_NN for_IN 1000_CD nursing_NN home_NN residents_NNS ._SENT Clearly_RB ,_, optimizing_VBG the_DT use_NN of_IN antibiotics_NNS in_IN this_DT population_NN is_VBZ an_DT important_JJ quality_NN of_IN care_NN priority_NN ._SENT Antibiotics_NNS for_IN urinary_JJ indications_NNS |_SYM Urinary_JJ tract_NN infections_NNS are_VBP the_DT most_RBS common_JJ indication_NN for_IN prescribing_VBG antibiotics_NNS for_IN residents_NNS in_IN LTCFs_NP ._SENT Urinary_JJ tract_NN infections_NNS alone_RB account_VBP for_IN 30_CD %_NN to_TO 56_CD %_NN of_IN all_DT prescriptions_NNS for_IN antibiotics_NNS in_IN that_DT population_NN ._SENT The_DT diagnosis_NN of_IN UTIs_NP ,_, like_IN respiratory_JJ and_CC other_JJ infections_NNS in_IN residents_NNS of_IN LTCFs_NP ,_, is_VBZ difficult_JJ ._SENT Clinical_JJ symptoms_NNS and_CC signs_NNS in_IN this_DT population_NN are_VBP often_RB vague_JJ and_CC non-specific_JJ ._SENT In_IN the_DT absence_NN of_IN valid_JJ diagnostic_JJ criteria_NNS ,_, it_PP is_VBZ difficult_JJ to_TO develop_VB a_DT strategy_NN to_TO optimize_VB antibiotic_JJ use_NN in_IN the_DT institutionalized_VBN elderly_JJ ._SENT Asymptomatic_JJ bacteriuria_NNS ,_, or_CC the_DT presence_NN of_IN bacteria_NNS in_IN the_DT urine_NN in_IN the_DT absence_NN of_IN urinary_JJ symptoms_NNS ,_, is_VBZ however_RB an_DT important_JJ exception_NN ._SENT This_DT condition_NN occurs_VBZ in_IN up_IN to_TO 50_CD %_NN of_IN older_JJR institutionalized_VBN women_NNS and_CC 35_CD %_NN of_IN institutionalized_VBD older_JJR men_NNS ._SENT It_PP is_VBZ important_JJ to_TO note_VB that_IN the_DT term_NN "_`` asymptomatic_JJ "_'' includes_VBZ bacteriuria_NN in_IN the_DT presence_NN of_IN non-specific_JJ ,_, non-urinary_JJ symptoms_NNS (_( e.g._FW malaise_NN ,_, fatigue_NN ,_, functional_JJ change_NN )_) ._SENT It_PP is_VBZ recommended_VBN that_IN asymptomatic_JJ bacteriuria_NNS be_VB treated_VBN in_IN populations_NNS at_IN high_JJ risk_NN of_IN developing_VBG subsequent_JJ infection_NN ,_, such_JJ as_IN children_NNS or_CC pregnant_JJ women_NNS ._SENT However_RB ,_, there_EX is_VBZ compelling_JJ evidence_NN to_TO support_VB not_RB treating_VBG asymptomatic_JJ bacteriuria_NNS in_IN residents_NNS of_IN long-term_JJ care_NN facilities_NNS ._SENT Data_NNS from_IN four_CD randomized_VBD controlled_JJ trials_NNS demonstrate_VBP a_DT lack_NN of_IN benefit_NN from_IN treating_VBG asymptomatic_JJ bacteriuria_NNS ._SENT These_DT trials_NNS ,_, conducted_VBN in_IN part_NN to_TO validate_VB the_DT finding_NN of_IN an_DT association_NN between_IN asymptomatic_JJ bacteriuria_NN and_CC death_NN ,_, found_VBD no_DT effect_NN of_IN antibiotic_JJ treatment_NN on_IN mortality_NN ._SENT Despite_IN clear_JJ evidence_NN that_WDT supports_VBZ not_RB treating_VBG asymptomatic_JJ bacteriuria_NNS ,_, institutionalized_VBD older_JJR adults_NNS are_VBP frequently_RB treated_VBN for_IN it_PP with_IN antibiotics_NNS ._SENT It_PP is_VBZ estimated_VBN that_IN about_RB one_CD third_NN of_IN all_DT prescriptions_NNS for_IN urinary_JJ indications_NNS in_IN nursing_NN homes_NNS are_VBP for_IN asymptomatic_JJ bacteriuria_NNS ._SENT In_IN a_DT 12-month_JJ antibiotic_JJ utilization_NN in_IN chronic_JJ care_NN study_NN ,_, 30_CD %_NN of_IN prescriptions_NNS for_IN a_DT urinary_JJ indication_NN were_VBD for_IN asymptomatic_JJ bacteriuria_NNS ._SENT Defining_VBG "_`` appropriate_JJ "_'' antibiotic_JJ use_NN for_IN most_JJS bacterial_JJ infections_NNS is_VBZ plagued_VBN with_IN difficulty_NN due_JJ to_TO diagnostic_JJ uncertainties_NNS ._SENT However_RB ,_, antibiotic_JJ prescribing_VBG for_IN urinary_JJ indications_NNS is_VBZ an_DT important_JJ exception_NN ._SENT Reducing_VBG inappropriate_JJ antibiotic_JJ use_NN for_IN urinary_JJ indications_NNS may_MD be_VB an_DT important_JJ tactic_NN for_IN optimizing_VBG the_DT use_NN of_IN antibiotics_NNS in_IN LTCFs_NP ._SENT Qualitative_JJ study_NN on_IN asymptomatic_JJ bacteriuria_NN |_SYM To_TO help_VB identify_VB strategies_NNS for_IN improving_VBG the_DT management_NN of_IN asymptomatic_JJ bacteriuria_NNS in_IN older_JJR adults_NNS in_IN residential_JJ LTCFs_NP ,_, a_DT qualitative_JJ study_NN on_IN reasons_NNS why_WRB antibiotics_NNS are_VBP prescribed_VBN for_IN this_DT condition_NN was_VBD conducted_VBN ._SENT This_DT study_NN revealed_VBD that_IN ordering_VBG urine_NN cultures_NNS and_CC prescribing_VBG antibiotics_NNS for_IN asymptomatic_JJ bacteriuria_NNS are_VBP largely_RB driven_VBN by_IN nonspecific_JJ ,_, non-urinary_JJ symptoms_NNS (_( e.g._FW malaise_NN ,_, confusion_NN ,_, agitation_NN )_) ._SENT Nurses_NNS ,_, who_WP order_NN urine_NN cultures_NNS and_CC influence_NN physicians_NNS decision_NN to_TO prescribe_VB antibiotics_NNS ,_, were_VBD key_JJ in_IN this_DT process_NN ._SENT Education_NN and_CC guidelines_NNS for_IN management_NN of_IN asymptomatic_JJ bacteriuria_NNS and_CC urinary_JJ tract_NN infection_NN were_VBD viewed_VBN by_IN study_NN respondents_NNS as_IN an_DT important_JJ priority_NN for_IN both_DT physicians_NNS and_CC nurses_NNS ._SENT Some_DT evidence_NN exists_VBZ to_TO suggest_VB that_IN systematic_JJ practise-based_JJ interventions_NNS are_VBP effective_JJ in_IN changing_VBG physician_NN performance_NN ._SENT Therefore_RB ,_, based_VBN on_IN the_DT best_RBS clinical_JJ evidence_NN and_CC our_PP$ own_JJ qualitative_JJ data_NNS ,_, we_PP have_VBP constructed_VBN clinical_JJ algorithms_NNS for_IN managing_VBG UTIs_NN in_IN older_JJR adults_NNS in_IN LTCFs_NP ._SENT This_DT paper_NN describes_VBZ the_DT protocol_NN of_IN an_DT on-going_JJ randomized_VBN trial_NN to_TO optimize_VB antibiotic_JJ use_NN in_IN residents_NNS of_IN nursing_NN homes_NNS using_VBG clinical_JJ algorithms_NNS ._SENT The_DT primary_JJ aim_NN of_IN this_DT study_NN is_VBZ to_TO determine_VB if_IN an_DT evidence-based_JJ clinical_JJ algorithm_NN for_IN managing_VBG urinary_JJ tract_NN infections_NNS (_( UTIs_NP )_) in_IN older_JJR adults_NNS in_IN residential_JJ long-term_JJ care_NN facilities_NNS (_( LTCFs_NP )_) can_MD reduce_VB the_DT overall_JJ use_NN of_IN antibiotics_NNS in_IN LTCFs_NP ._SENT Secondary_JJ study_NN questions_NNS include_VBP :_: Does_VBZ the_DT use_NN of_IN a_DT diagnostic_JJ algorithm_NN reduce_VB the_DT number_NN of_IN urine_NN cultures_NNS ordered_VBN for_IN residents_NNS in_IN LTCFs_NP without_IN urinary_JJ symptoms_NNS ?_SENT Does_VBZ the_DT use_NN of_IN a_DT treatment_NN algorithm_NN reduce_VB the_DT number_NN of_IN antibiotic_JJ courses_NNS prescribed_VBN for_IN presumptive_JJ UTIs_NN in_IN the_DT target_NN population_NN ?_SENT Study_NN population_NN |_SYM Twenty-two_NP pairs_NNS of_IN nursing_NN homes_NNS have_VBP been_VBN enrolled_VBN ._SENT Only_RB free_JJ standing_NN ,_, community-based_JJ residential_JJ LTCFs_NNS are_VBP eligible_JJ ._SENT Other_JJ eligibility_NN criteria_NNS include_VBP the_DT following_VBG :_: 1_LS )_) the_DT facility_NN has_VBZ 100_CD or_CC more_JJR residents_NNS ;_: 2_LS )_) the_DT LTCF_NP does_VBZ not_RB have_VB a_DT stated_JJ policy_NN for_IN diagnosis_NN or_CC treatment_NN of_IN urinary_JJ tract_NN infections_NNS ;_: 3_LS )_) the_DT LTCF_NP agrees_VBZ to_TO refrain_VB from_IN introducing_VBG new_JJ management_NN strategies_NNS for_IN antibiotic_JJ utilization_NN or_CC clinical_JJ pathways_NNS for_IN urinary_JJ tract_NN infection_NN during_IN the_DT study_NN ._SENT To_TO enhance_VB representation_NN for_IN residential_JJ LTCFs_NP in_IN the_DT community_NN ,_, the_DT study_NN will_MD be_VB limited_VBN to_TO LTCFs_NP not_RB directly_RB associated_VBN with_IN tertiary_JJ care_NN centres_NNS ._SENT The_DT design_NN is_VBZ randomized_VBN matched_VBN pairs_NNS ._SENT Within_IN each_DT of_IN the_DT 11_CD pairs_NNS of_IN LTCFs_NP ,_, one_CD was_VBD randomized_VBN to_TO the_DT intervention_NN (_( clinical_JJ algorithm_NN )_) ,_, the_DT other_JJ half_NN to_TO "_`` usual_JJ "_'' management_NN ._SENT Quantitative_JJ outcomes_NNS will_MD include_VB 1_CD )_) the_DT proportion_NN of_IN antibiotic_JJ courses_NNS prescribed_VBN for_IN urinary_JJ indications_NNS ,_, 2_LS )_) the_DT total_JJ number_NN of_IN courses_NNS of_IN antibiotics_NNS used_VBN ,_, 3_CD )_) rates_NNS of_IN urine_NN cultures_NNS ordered_VBD ,_, 4_CD )_) hospitalization_NN rates_NNS for_IN urinary_JJ tract_NN infections_NNS ,_, and_CC 5_LS )_) mortality_NN rates_NNS ._SENT Within_IN a_DT LTCF_NP ,_, randomization_NN of_IN individual_JJ healthcare_NN providers_NNS or_CC residents_NNS to_TO the_DT algorithm_NN likely_RB would_MD introduce_VB bias_NN due_JJ to_TO contamination_NN ._SENT Therefore_RB ,_, for_IN the_DT quantitative_JJ component_NN of_IN this_DT study_NN ,_, the_DT nursing_NN home_NN will_MD serve_VB as_IN the_DT unit_NN of_IN allocation_NN and_CC analysis_NN ._SENT Figure_NP 1_CD |_SYM Diagnostic_JJ algorithm_NN Diagnostic_JJ algorithm_NN ._SENT This_DT algorithm_NN guides_VBZ physicians_NNS and_CC nurses_NNS in_IN the_DT ordering_VBG of_IN urine_NN cultures_NNS for_IN nursing_VBG home_NN residents_NNS with_IN suspected_JJ infections_NNS ._SENT Figure_NP 2_CD |_SYM Treatment_NP algorithm_NN ._SENT Treatment_NN algorithm_NN ._SENT This_DT algorithm_NN allows_VBZ physicians_NNS and_CC nurses_NNS to_TO optimize_VB antibiotic_JJ use_NN in_IN residents_NNS with_IN suspected_JJ infections_NNS ._SENT Intervention_NN :_: an_DT evidence-based_JJ clinical_JJ algorithm_NN |_SYM Although_IN treatment_NN guidelines_NNS for_IN infections_NNS are_VBP abundant_JJ in_IN the_DT literature_NN (_( e.g_JJ community-acquired_JJ pneumonia_NN )_) few_JJ diagnostic_NN or_CC treatment_NN algorithms_NNS for_IN infections_NNS have_VBP been_VBN systematically_RB evaluated_VBN for_IN outcome_NN ._SENT A_DT management_NN algorithm_NN for_IN UTIs_NP in_IN nursing_VBG homes_NNS has_VBZ been_VBN proposed_VBN ._SENT However_RB ,_, no_DT algorithms_NNS for_IN optimizing_VBG antimicrobial_JJ use_NN or_CC for_IN managing_VBG infections_NNS have_VBP been_VBN evaluated_VBN in_IN LTCFs_NP ._SENT Nursing_NN staff_NN (_( RNs_NP and_CC RPNs_NP )_) play_VBP a_DT critical_JJ role_NN in_IN the_DT clinical_JJ management_NN of_IN LTCF_NP residents_NNS ._SENT Physicians_NNS spend_VBP relatively_RB little_JJ time_NN at_IN the_DT bedside_NN in_IN LTCFs_NP ,_, and_CC must_MD rely_VB heavily_RB on_IN nursing_NN assessments_NNS ._SENT Therefore_RB ,_, an_DT intervention_NN to_TO change_VB clinical_JJ practise_VBP in_IN LTCFs_NP ideally_RB must_MD 1_CD )_) be_VB evidence-based_JJ ,_, 2_CD )_) be_VB feasible_JJ to_TO implement_VB ,_, 3_CD )_) be_VB inexpensive_JJ ,_, 4_CD )_) involve_VBP both_DT nurses_NNS and_CC physicians_NNS ,_, 5_LS )_) have_VBP the_DT potential_NN for_IN strong_JJ "_`` buy-in_NN "_'' from_IN both_DT physicians_NNS and_CC nurses_NNS ,_, and_CC 6_CD )_) be_VB evaluable_JJ in_IN terms_NNS of_IN outcomes_NNS ._SENT We_PP believe_VBP that_IN our_PP$ clinical_JJ algorithm_NN for_IN the_DT diagnosis_NN and_CC treatment_NN of_IN UTIs_NP in_IN residents_NNS of_IN LTCFs_NP will_MD meet_VB these_DT criteria_NNS ._SENT A_DT draft_NN diagnostic_NN and_CC a_DT treatment_NN algorithm_NN was_VBD developed_VBN using_VBG the_DT best_JJS evidence_NN available_JJ ,_, augmented_VBN with_IN feedback_NN from_IN primary_JJ care_NN physicians_NNS and_CC nurses_NNS working_VBG in_IN residential_JJ LTCFs_NP (_( Figure_NP +_SYM )_) ._SENT Since_IN there_EX is_VBZ no_DT treatment_NN benefit_NN for_IN asymptomatic_JJ bacteriuria_NNS ,_, the_DT algorithms_NNS indicate_VBP that_IN urine_NN should_MD not_RB be_VB cultured_VBN in_IN the_DT absence_NN of_IN fever_NN or_CC urinary_JJ symptoms_NNS ,_, nor_CC should_MD antibiotics_NNS be_VB prescribed_VBN for_IN positive_JJ cultures_NNS ._SENT In_IN the_DT absence_NN of_IN any_DT urinary_JJ symptoms_NNS ,_, only_RB 10_CD %_NN of_IN LTCF_NP residents_NNS with_IN fever_NN and_CC bacteriuria_NNS actually_RB have_VBP a_DT urinary_JJ infection_NN (_( positive_JJ predictive_JJ value_NN of_IN urine_NN culture_NN for_IN urinary_JJ infection_NN in_IN the_DT setting_NN of_IN fever_NN is_VBZ 17_CD %_NN )_) (_( 35_CD )_) ._SENT Therefore_RB ,_, prior_RB to_TO ordering_VBG a_DT culture_NN other_JJ common_JJ infections_NNS (_( respiratory_JJ or_CC skin_NN and_CC soft_JJ tissue_NN )_) need_VBP to_TO be_VB ruled_VBN out_RP ._SENT When_WRB urinary_JJ symptoms_NNS are_VBP present_JJ (_( in_IN the_DT setting_NN of_IN bacteriuria_NN and_CC fever_NN )_) ,_, about_RB 50_CD %_NN of_IN episodes_NNS are_VBP ,_, serologically_RB ,_, urinary_JJ infections_NNS ._SENT Clinical_JJ evaluation_NN for_IN other_JJ infections_NNS should_MD therefore_RB also_RB be_VB conducted_VBN in_IN such_JJ instances_NNS prior_RB to_TO instituting_VBG antibiotic_JJ therapy_NN ._SENT A_DT negative_JJ urine_NN culture_NN effectively_RB rules_VBZ out_RP a_DT urinary_JJ infection_NN (_( so_RB long_RB as_IN previous_JJ antibiotics_NNS were_VBD not_RB prescribed_VBN )_) ._SENT Although_IN bacteriuria_NN in_IN the_DT setting_NN of_IN pyuria_NN is_VBZ often_RB interpreted_VBN as_IN a_DT "_`` true_JJ infection_NN "_'' ,_, studies_NNS have_VBP shown_VBN that_IN over_IN 90_CD %_NN of_IN the_DT institutionalized_VBN elderly_JJ with_IN bacteriuria_NNS also_RB have_VBP pyuria_NN ._SENT Therefore_RB the_DT presence_NN of_IN pyuria_NN and_CC bacteriuria_NN is_VBZ not_RB helpful_JJ ._SENT However_RB ,_, the_DT absence_NN of_IN pyuria_NN suggests_VBZ the_DT absence_NN of_IN a_DT host_NN response_NN (_( i.e._FW absence_NN of_IN infection_NN )_) ,_, therefore_RB bacteriuria_NNS in_IN the_DT absence_NN of_IN pyuria_NN indicates_VBZ that_IN a_DT urinary_JJ tract_NN infection_NN is_VBZ unlikely_JJ ._SENT Gross_JJ hematuria_NN in_IN the_DT institutionalized_VBN elderly_NN generally_RB represents_VBZ an_DT underlying_VBG structural_JJ abnormality_NN in_IN the_DT genitourinary_JJ tract_NN ._SENT About_RB 70_CD %_NN of_IN individuals_NNS with_IN gross_JJ hematuria_NN also_RB have_VBP bacteriuria_NN ._SENT Since_IN as_RB many_JJ as_IN 25_CD %_NN of_IN individuals_NNS who_WP develop_VBP hematuria_NN subsequently_RB become_VBN febrile_JJ ,_, treatment_NN of_IN the_DT resident_NN with_IN fever_NN ,_, gross_JJ hematuria_NN and_CC bacteriuria_NN is_VBZ necessary_JJ due_RB to_TO secondary_JJ invasive_JJ infection_NN ._SENT Since_IN there_EX is_VBZ no_DT relationship_NN between_IN the_DT presence_NN or_CC absence_NN of_IN bacteriuria_NN and_CC non-urinary_JJ symptoms_NNS ,_, only_RB urinary_JJ symptoms_NNS will_MD be_VB assessed_VBN in_IN the_DT diagnostic_JJ or_CC treatment_NN algorithm_NN ._SENT Adoption_NN of_IN the_DT algorithms_NNS |_SYM The_DT algorithms_NNS were_VBD pilot-tested_VBN in_IN four_CD nursing_NN homes_NNS prior_RB to_TO the_DT start_NN of_IN the_DT actual_JJ trial_NN ._SENT For_IN the_DT trial_NN ,_, adoption_NN of_IN the_DT intervention_NN has_VBZ been_VBN through_IN in-services_NN with_IN physicians_NNS and_CC nursing_VBG staff_NN using_VBG case-scenarios_NNS to_TO explain_VB the_DT use_NN of_IN the_DT algorithms_NNS ._SENT The_DT algorithms_NNS were_VBD printed_VBN on_IN pocket_NN cards_NNS and_CC distributed_VBN to_TO physicians_NNS and_CC nursing_NN staff_NN at_IN the_DT start_NN of_IN the_DT study_NN ._SENT The_DT algorithms_NNS are_VBP also_RB kept_VBN at_IN all_DT nursing_NN stations_NNS using_VBG large_JJ posters_NNS ._SENT On-site_JJ visits_NNS are_VBP planned_VBN to_TO help_VB with_IN adherence_NN to_TO the_DT protocol_NN ._SENT Data_NNS collection_NN |_SYM Demographics_NP of_IN the_DT residents_NNS and_CC features_NNS about_IN the_DT facilities_NNS will_MD be_VB collected_VBN ._SENT Other_JJ data_NNS include_VBP the_DT name_NN and_CC dose_NN of_IN the_DT antibiotic_NN ,_, route_NN of_IN administration_NN ,_, start_VB and_CC stop_VB date_NN ,_, reason_NN for_IN the_DT prescription_NN ,_, as_RB well_RB as_IN urinary_JJ symptoms_NNS leading_VBG to_TO the_DT prescription_NN ,_, whether_IN a_DT urine_NN culture_NN was_VBD ordered_VBN ,_, and_CC if_IN so_RB ,_, its_PP$ result_NN ._SENT Information_NN on_IN deaths_NNS ,_, all_DT cause_NN hospitalizations_NNS ,_, and_CC hospitalizations_NNS for_IN urinary_JJ sepsis_NN is_VBZ being_VBG collected_VBN ._SENT Analysis_NN |_SYM The_DT unit_NN of_IN analysis_NN for_IN this_DT study_NN is_VBZ the_DT nursing_NN home_NN ._SENT A_DT paired_VBN t-test_NN will_MD be_VB used_VBN to_TO analyse_VB the_DT within-pair_JJ differences_NNS between_IN the_DT proportions_NNS of_IN antibiotics_NNS prescribed_VBN for_IN urinary_JJ indications_NNS in_IN matched_VBN pairs_NNS of_IN nursing_NN homes_NNS ._SENT In_IN this_DT way_NN ,_, the_DT fact_NN that_IN the_DT denominator_NN of_IN the_DT proportions_NNS is_VBZ also_RB an_DT outcome_NN is_VBZ taken_VBN into_IN consideration_NN ._SENT Differences_NNS in_IN rates_NNS of_IN overall_JJ antibiotic_JJ use_NN (_( antibiotic_JJ courses_NNS per_IN 1000_CD resident_JJ days_NNS )_) will_MD be_VB compared_VBN using_VBG a_DT paired_VBN t-test_NN ._SENT Rates_NNS of_IN antibiotic_JJ use_NN for_IN urinary_JJ indications_NNS (_( antibiotic_JJ courses_NNS per_IN 1000_CD resident_JJ days_NNS and_CC defined_VBN daily_JJ dosages/1000_NN resident_NN days_NNS )_) ,_, rates_NNS of_IN urine_NN cultures_NNS obtained_VBN (_( urine_NN cultures_NNS per_IN 1000_CD resident_JJ days_NNS )_) ,_, rates_NNS of_IN hospitalization_NN (_( per_IN 1000_CD resident_JJ days_NNS )_) ,_, and_CC overall_JJ mortality_NN rates_NNS will_MD be_VB compared_VBN using_VBG paired_VBN t-tests_NNS and_CC Wilcoxon_NP signed_VBD rank_JJ tests_NNS ._SENT Logistic_JJ regression_NN analysis_NN is_VBZ planned_VBN to_TO account_VB for_IN potentially_RB important_JJ co-variates_NNS such_JJ as_IN proportion_NN of_IN residents_NNS bed/wheelchair_NN bound_NN and_CC pharmacy_NN automatic_JJ stop_NN dates_NNS ._SENT Sample_NN size_NN calculation_NN |_SYM In_IN our_PP$ 12_CD month_NN study_NN of_IN antibiotic_JJ utilization_NN in_IN Ontario_NP long-term_JJ care_NN facilities_NNS ,_, 30_CD %_NN of_IN all_DT antibiotic_JJ prescriptions_NNS were_VBD for_IN urinary_JJ indications_NNS ,_, of_IN which_WDT one_CD third_NN were_VBD for_IN asymptomatic_JJ bacteriuria_NNS ._SENT We_PP believe_VBP that_IN the_DT algorithm_NN will_MD lead_VB to_TO at_IN least_JJS a_DT 20_CD %_NN reduction_NN in_IN the_DT overall_JJ use_NN of_IN antibiotics_NNS ,_, that_WDT is_VBZ ,_, a_DT reduction_NN in_IN the_DT proportion_NN of_IN antibiotic_JJ prescriptions_NNS for_IN urinary_JJ indications_NNS from_IN 30_CD %_NN to_TO 10_CD %_NN ._SENT To_TO detect_VB this_DT difference_NN ,_, for_IN an_DT alpha_NN of_IN 0.05_CD and_CC 80_CD %_NN power_NN ,_, a_DT total_NN of_IN 142_CD prescriptions_NNS (_( 71_CD in_IN each_DT arm_NN )_) is_VBZ needed_VBN ._SENT To_TO adjust_VB for_IN the_DT effect_NN of_IN within_IN cluster_NN dependency_NN ,_, the_DT intracluster_NN correlation_NN coefficient_NN (_( between_IN home_NN variance_NN for_IN urinary_JJ antibiotic_JJ prescription_NN /_SYM sum_NN of_IN inter-_NN and_CC intra-home_NN variance_NN )_) ,_, was_VBD then_RB calculated_VBN using_VBG data_NNS from_IN the_DT 12_CD month_NN study_NN in_IN Ontario_NP long-term_JJ care_NN facilities_NNS ._SENT The_DT proportion_NN of_IN antibiotics_NNS prescribed_VBN for_IN a_DT urinary_JJ indication_NN was_VBD 0.32_CD (_( p_NN )_) and_CC the_DT variance_NN 0.009_CD (_( between_IN home_NN variance_NN )_) ._SENT The_DT intra-home_NN variance_NN ,_, given_VBN by_IN the_DT binomial_JJ distribution_NN [_SYM (_( p_NN )_) (_( 1-p_JJ )_) ]_SYM ,_, was_VBD 0.21_CD ._SENT Therefore_RB ,_, the_DT intracluster_NN correlation_NN coefficient_NN is_VBZ 0.04_CD ._SENT Donner_NP et_FW al._FW (_( 41_LS )_) describe_VB a_DT variance_NN inflation_NN factor_NN given_VBN by_IN 1_CD +_SYM (_( n_NN -_: 1_LS )_) tau_NN ,_, where_WRB tau_NN is_VBZ the_DT intracluster_JJ correlation_NN coefficient_NN ,_, and_CC n=_JJ samples_NNS (_( prescriptions_NNS )_) needed_VBN per_IN cluster_NN ._SENT Since_IN 23_CD prescriptions_NNS can_MD be_VB obtained_VBN per_IN home_NN per_IN month_NN (_( based_VBN on_IN the_DT average_JJ LTCF_NN in_IN our_PP$ Canada-US_NP study_NN )_) ,_, and_CC if_IN data_NN collection_NN is_VBZ conducted_VBN over_IN 11_CD months_NNS ,_, then_JJ n_NN =_SYM 253_CD ._SENT Using_VBG the_DT formula_NN given_VBN above_IN ,_, the_DT variance_NN inflation_NN factor_NN is_VBZ 11_CD ._SENT Therefore_RB ,_, 1562_CD (_( 142_CD x_SYM 11_CD )_) urinary_JJ prescriptions_NNS are_VBP required_VBN ._SENT Since_IN these_DT represent_VBP 30_CD %_NN of_IN antibiotic_JJ prescriptions_NNS ,_, 5206_CD prescriptions_NNS need_VBP to_TO be_VB collected_VBN in_IN total_NN ._SENT This_DT means_VBZ that_IN 20_CD or_CC 10_CD pairs_NNS of_IN nursing_NN homes_NNS will_MD need_VB to_TO be_VB followed_VBN for_IN 12_CD months_NNS ._SENT Since_IN matching_NN ,_, which_WDT would_MD improve_VB efficiency_NN ,_, was_VBD not_RB accounted_VBN for_IN in_IN the_DT sample_NN size_NN calculation_NN ,_, these_DT figures_NNS are_VBP a_DT conservative_JJ estimate_NN ._SENT We_PP will_MD recruit_VB another_DT two_CD homes_NNS to_TO maintain_VB the_DT target_NN sample_NN size_NN in_IN case_NN a_DT pair_NN of_IN homes_NNS withdraws_VBZ from_IN the_DT study_NN ._SENT Qualitative_JJ component_NN |_SYM To_TO evaluate_VB the_DT process_NN of_IN adopting_VBG the_DT proposed_VBN algorithms_NNS in_IN LTCFs_NP ,_, we_PP plan_VBP to_TO conduct_VB focus_NN groups_NNS and_CC semi-structured_JJ interviews_NNS ._SENT Two_CD groups_NNS of_IN respondents_NNS will_MD be_VB interviewed_VBN ,_, key_JJ clinical_JJ administrators_NNS in_IN the_DT participating_VBG LTCFs_NP (_( medical_JJ directors_NNS ,_, directors_NNS of_IN nursing_NN ,_, infection_NN control_NN officers_NNS )_) ,_, and_CC staff_NN who_WP will_MD implement_VB the_DT algorithms_NNS (_( RN_NN and_CC RPN_NP )_) ._SENT Standard_JJ methods_NNS to_TO ensure_VB that_IN the_DT qualitative_JJ data_NNS are_VBP gathered_VBN and_CC analyzed_VBN rigorously_RB will_MD be_VB followed_VBN throughout_IN the_DT study_NN ._SENT These_DT include_VBP member_NN checking_NN (_( asking_VBG respondents_NNS to_TO review_VB our_PP$ findings_NNS )_) ,_, peer_NN review_NN (_( asking_VBG colleagues_NNS to_TO review_VB our_PP$ research_NN process_NN )_) ,_, and_CC an_DT audit_NN trail_NN (_( creating_VBG documents_NNS which_WDT outline_VBP all_DT decisions_NNS made_VBN throughout_IN the_DT investigation_NN )_) ._SENT Each_DT of_IN these_DT steps_NNS will_MD be_VB taken_VBN in_IN this_DT study_NN to_TO ensure_VB that_IN this_DT portion_NN of_IN the_DT study_NN is_VBZ rigorous_JJ and_CC findings_NNS are_VBP trustworthy_JJ ._SENT None_NN declared_VBD ._SENT All_DT authors_NNS contributed_VBD to_TO the_DT development_NN of_IN the_DT protocol_NN of_IN this_DT randomized_VBN trial_NN ._SENT Mark_NP Loeb_NP wrote_VBD the_DT original_JJ draft_NN of_IN this_DT paper_NN and_CC all_DT authors_NNS offered_VBD critical_JJ revisions_NNS ._SENT publication_NN history_NN :_: The_DT pre-publication_NN history_NN for_IN this_DT paper_NN can_MD be_VB accessed_VBN here_RB :_: 